Gala­pa­gos seeks 's­trate­gic op­tion­s' for Jy­s­e­le­ca as JAK in­hibitor sales dis­ap­point again

Gala­pa­gos is as­sess­ing “var­i­ous strate­gic op­tions” with Jy­s­e­le­ca, the JAK in­hibitor that once in­spired block­buster pro­jec­tions but re­peat­ed­ly dis­ap­point­ed.

The Bel­gian biotech at­trib­uted the move …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER